Topiramate as add‐on treatment for patients with bipolar mania
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective: Anticonvulsant agents such as carbamazepine and valproate are alternatives to lithium in treating subjects with bipolar disorder. Topiramate (Topamax®), a new antiepileptic agent, is a candidate drug for bipolar disorder. We evaluated topiramate as adjunctive treatment for bipolar patients. Methods: Eighteen patients with DSM‐IV bipolar I disorder [mania (n=12), hypomania (n=1), mixed episode (n=5), and rapid cycling (n=6)], and two subjects with schizoaffective disorder – bipolar type, resistant to current mood‐stabilizer treatment were initiated on topiramate, 25 mg/day, increasing by 25–50 mg every 3–7 days to a target dose between 100 and 300 mg/day, as other medications were held constant for 5 weeks. The Young Mania Rating Scale (Y‐MRS), Hamilton Depression Rating Scale (Ham‐D), and Clinical Global Impression‐Bipolar Version Scale (CGI‐BP) were used to rate subjects weekly. Results: By 5 weeks, 12 (60%) subjects were responders, i.e., 50% reduction in the Y‐MRS scores and a CGI of ‘much’ or ‘very much improved’. Three subjects were ‘minimally improved’, four showed no change, and one was ‘minimally worse’. Six subjects had parasthesia, three experienced fatigue, and two had ‘word‐finding’ difficulties; in all cases, side effects were transient. All patients lost weight with a mean of 9.4 lb in 5 weeks, and a significant reduction in body mass index (BMI) occurred too. Conclusions: Topiramate appears to have efficacy for the manic and mixed phases of bipolar illness. Other preliminary data suggest antidepressant efficacy too. Among obese bipolar subjects, the weight loss potential of topiramate may be beneficial. If controlled trials confirm these initial results, topiramate may be a significant addition to the available treatments for bipolar disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Cited by
Antipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities
McIntyre, R. S., McCann, S. M., & Kennedy, S. H. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600308 · Cited by 261
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“The open-label study by Chengappa et al. (1999) also included patients resistant to mood stabiliser or antipsychotic treatment; out of the five mixed patients included, three (60”
MethodKonovalov, S., Muralee, S., & Tampi, R. R. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207006540 · Cited by 126
Acute and prophylactic effects of anticonvulsants in bipolar depression
Post, R. M., Speer, A. M., Obrocea, G. V., & Leverich, G. S. (2002) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(02)00047-6 · Cited by 20
Metadata
- Authors
- Roy Chengappa, K., Rathore, D., Levine, J., Atzert, R., Solai, L., Parepally, H., Levin, H., Moffa, N., Delaney, J., & Brar, J. S.
- Venue
- Bipolar Disorders
- Publisher
- Wiley
- Published
- 1999-09
- Volume
- 1
- Issue
- 1
- Pages
- 42-53
- ISSN
- 1398-5647 (ISSN-L)
- 1399-5618
- OpenAlex
- W1964800048
- Cited by
- 153
- References
- 1
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topiramate as add‐on treatment for patients with bipolar mania. https://app.cochat.ai/papers/10.1034/j.1399-5618.1999.10111.x
- The paper
- Roy Chengappa, K., Rathore, D., Levine, J., Atzert, R., Solai, L., Parepally, H., Levin, H., Moffa, N., Delaney, J., & Brar, J. S. (1999). Topiramate as add‐on treatment for patients with bipolar mania. Bipolar Disorders. https://doi.org/10.1034/j.1399-5618.1999.10111.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.